Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor–Resistant Clear Cell Renal Cell Carcinoma()

PURPOSE: Although targeting angiogenesis with tyrosine kinase inhibitors (TKIs) has become standard of care in the treatment of clear cell renal cell carcinoma (RCC), resistance mechanism are not fully understood, and there is a need to develop new therapeutic options overcoming them. METHODS AND MA...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Jiryeon, Rath, Oliver, Schueler, Julia, Sung, Hyun Hwan, Jeon, Hwang Gyun, Jeong, Byong Chang, Seo, Seong Il, Jeon, Seong Soo, Lee, Hyun Moo, Choi, Han-Yong, Kwon, Ghee-Young, Park, Woong Yang, Lee, Jeeyun, Park, Se Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358930/
https://www.ncbi.nlm.nih.gov/pubmed/28325666
http://dx.doi.org/10.1016/j.tranon.2017.01.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358930/
https://www.ncbi.nlm.nih.gov/pubmed/28325666
http://dx.doi.org/10.1016/j.tranon.2017.01.016

Ejemplares similares